The LIT - Leibniz Institute for Immunotherapy (foundation under civil law) (https://lit.eu) – is a biomedical research center focusing on translational immunology in the fields of cancer immunotherapy, transplant rejection and autoimmunity. The objective of the LIT is to develop innovative and efficient cellular immune therapeutics in these areas. Our own GMP laboratories and close networking with University and University Hospital offer excellent opportunities for clinical translation of novel immune cell products.
The Division “Functional Immune Cell Modulation” at the LIT is recruiting a
in part-time position (65 %), starting as soon as possible. This position is initially limited to three years, with the possibility of extension.
We are seeking a motivated and curious PhD candidate to join our research group working at the intersection of CAR T-cell engineering, T-cell biology, and the treatment of B-cell malignancies. This project tackles one of the central obstacles facing adoptive cell therapy: immunosuppression in the tumor microenvironment.
IL-10 is emerging as a critical Achilles' heel limiting the functionality of donor-derived CD19-CAR CD8⁺ T memory stem cells (TSCM) used to treat B-cell malignancies that relapse after allogeneic stem cell transplantation. While TSCM cells offer exceptional persistence and self-renewal, IL-10-mediated signaling appears to blunt their therapeutic potential. Understanding and reversing this effect could meaningfully improve outcomes for patients with few remaining options.
Your tasks
The goal of this project is to elucidate the role of IL-10 in CAR TSCM cell biology and to develop engineering strategies that turn this liability into an advantage. You will design, build, and test CAR TSCM cells equipped with:
-
Dominant-negative IL-10 receptors to shield cells from immunosuppressive signaling
-
IL-10 switch receptors that convert inhibitory IL-10 input into T-cell–supportive signals
-
Synthetic intramembrane proteolysis receptors designed to sustain stemness in response to IL-10
Your work will combine molecular and synthetic biology, primary human T-cell engineering, functional immunoassays, and mechanistic studies of TSCM differentiation and persistence.
Our Requirements
-
A Master's degree (or equivalent) in molecular biology, immunology, biotechnology, biomedicine, or a related field
-
Hands-on experience with mammalian cell culture; experience with primary T cells, flow cytometry, molecular cloning, or viral vectors is a strong advantage
-
A genuine interest in immunotherapy andå synthetic receptor design
-
Strong analytical skills, scientific curiosity, and the ability to work both independently and within a collaborative team
-
Excellent command of written and spoken English
We offer:
-
A varied and exciting role in an innovative research environment
-
A dynamic and dedicated team committed to the future of cell therapies
-
Comprehensive training on state-of-the-art methods
-
Flat hierarchies and short decision-making processes
-
Excellent opportunities for professional and personal development
-
Flexible working hours to help balance family and career
-
Company pension scheme (VBL)
-
Annual special payment
-
Capital-forming benefits
-
Job ticket, and more
Remuneration is in accordance with TV-L.
The LIT places particular emphasis on promoting a healthy work-life balance.
Applicants with severe disabilities (m/f/d) will be given preference in the event of essentially equal suitability. Please indicate any disability in your application.
Please note that expenses that may arise in the context of an eventual job interview cannot be reimbursed.
For more information, please contact Prof. Luca Gattinoni (luca.gattinoni@lit.eu).
We are looking forward to receiving your detailed application. Please apply via our Online - Application Portal quoting the reference LG-2026-3.
Application deadline is July 03, 2026.